When will CagriSema be approved?

No approval date exists. Company guidance points to an FDA decision in Q4 2026, and no PDUFA date has been publicly confirmed.

Will it be available in the UK?

Not on the basis of an FDA decision. UK availability requires a separate MHRA authorisation, and NHS funding a separate NICE appraisal after that.

Why does REDEFINE 2 report a lower figure?

It enrolled adults with type 2 diabetes, in whom weight reduction is attenuated across the whole incretin class. Comparisons should be made within population.

Research & Regulatory News

CagriSema FDA Filing: Where the Review Stands

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Novo Nordisk submitted CagriSema to the FDA in December 2025, supported by the REDEFINE Phase 3 programme. Company guidance points to a decision in the fourth quarter of 2026. It would be the first once-weekly fixed combination of a GLP-1 analogue and an amylin analogue for weight management.

Key facts

Filed with FDA: December 2025
Supporting programme: REDEFINE Phase 3
Expected decision: Q4 2026 (company guidance)
PDUFA date: Not publicly confirmed
REDEFINE 1: 20.4% / 22.7% at 68 weeks
REDEFINE 2: 15.7% at 68 weeks (type 2 diabetes)
UK status: No MHRA authorisation

What has been filed

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, an approved GLP-1 receptor agonist, both administered once weekly. Novo Nordisk submitted it to the FDA in December 2025 for chronic weight management. It would be the first once-weekly combination of GLP-1 and amylin analogues to reach the market.

The evidence supporting it

REDEFINE 1, in adults with obesity and without diabetes, reported 20.4% mean weight reduction at 68 weeks across all randomised participants and 22.7% among those who adhered to treatment, against 3.0% and 2.3% on placebo. REDEFINE 2, in adults with type 2 diabetes, reported 15.7% against 3.1% on placebo. The lower figure in the diabetic population is the expected pattern across the entire incretin class rather than a weakness specific to this combination.

What a filing does and does not mean

Submission opens a review; it does not indicate an outcome. The agency assesses the full dossier including manufacturing and long-term safety, and may request additional data. Company guidance about a decision window is a projection, not a commitment by the regulator. No PDUFA date had been publicly confirmed by either party.

The UK position

An FDA submission has no bearing on UK availability. CagriSema holds no MHRA authorisation, and any UK approval would follow a separate application and assessment, then a separate NICE appraisal before NHS funding. The gap between those steps is typically a year or more, as the orforglipron timeline illustrates.

How it would sit against what exists

If approved, CagriSema's 20.4% would place it above tirzepatide's head-to-head result against semaglutide but below retatrutide's Phase 3 figures. Retatrutide remains investigational with an FDA filing signalled for the first quarter of 2027, so the competitive picture in 2027 would look different from the one a 2026 approval would enter.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

When will CagriSema be approved?: No approval date exists. Company guidance points to an FDA decision in Q4 2026, and no PDUFA date has been publicly confirmed.
Will it be available in the UK?: Not on the basis of an FDA decision. UK availability requires a separate MHRA authorisation, and NHS funding a separate NICE appraisal after that.
Why does REDEFINE 2 report a lower figure?: It enrolled adults with type 2 diabetes, in whom weight reduction is attenuated across the whole incretin class. Comparisons should be made within population.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum